CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vogenx, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vogenx, Inc.
3901 BARRETT DRIVE, SUITE 300
Phone: (919) 659-5677p:919 659-5677 RALEIGH, NC  27609  United States Ticker: VOGXVOGX
Business Summary
Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The Company's primary objective is to advance its lead product candidate, mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome, or GDCS. Mizagliflozin is a selective inhibitor of SGLT1, a glucose transporter present in the gastrointestinal tract responsible for transporting dietary glucose into the bloodstream. Its VGX-2857 is a novel small molecule-based product candidate that is orally available. VGX-2857 is a combination of two novel small molecules that have demonstrated the potential to aid in weight loss in one fixed dosage form.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman and Member of Board of Director, President, Chief Executive Officer JamesGreen 57 2/1/2021 2/1/2021
Chief Financial Officer, Corporate Secretary, Director StevenDelmar 70 2/1/2021 2/1/2021
Chief Scientific Officer, Director WilliamWilkison 65 2/1/2021 2/1/2021
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 4 (As of 5/15/2026)
Outstanding Shares: 13,917,587 (As of 3/31/2026)
Stock Exchange: NASD
Federal Tax Id: 863697324
Fax Number: (302) 658-3694


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, August 27, 2026